| Tumor microenvironment dynamics in clear-cell renal cell carcinoma L Vuong, RR Kotecha, MH Voss, AA Hakimi Cancer discovery 9 (10), 1349-1357, 2019 | 268 | 2019 |
| Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy C Krishna, RG DiNatale, F Kuo, RM Srivastava, L Vuong, D Chowell, ... Cancer cell 39 (5), 662-677. e6, 2021 | 203 | 2021 |
| Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial AA Hakimi, MH Voss, F Kuo, A Sanchez, M Liu, BG Nixon, L Vuong, ... Cancer discovery 9 (4), 510-525, 2019 | 193 | 2019 |
| Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study A Sanchez, H Furberg, F Kuo, L Vuong, Y Ged, S Patil, I Ostrovnaya, ... The Lancet Oncology 21 (2), 283-293, 2020 | 149 | 2020 |
| Improved prediction of immune checkpoint blockade efficacy across multiple cancer types D Chowell, SK Yoo, C Valero, A Pastore, C Krishna, M Lee, D Hoen, ... Nature biotechnology 40 (4), 499-506, 2022 | 147 | 2022 |
| An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade L Vuong, E Kouverianou, CM Rooney, BJ McHugh, SEM Howie, ... Cancer research 79 (7), 1480-1492, 2019 | 112 | 2019 |
| Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer BG Nixon, F Kuo, LL Ji, M Liu, K Capistrano, M Do, RA Franklin, X Wu, ... Immunity 55 (11), 2044-2058. e5, 2022 | 61 | 2022 |
| Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov. 2019 … AA Hakimi, MH Voss, F Kuo, A Sanchez, M Liu, BG Nixon, L Vuong, ... DOI: https://doi. org/10.1158/2159-8290. CD-18-0957. PMID: https://www. ncbi …, 0 | 51 | |
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity X Ma, N Riaz, RM Samstein, M Lee, V Makarov, C Valero, D Chowell, ... Nature genetics 54 (7), 996-1012, 2022 | 36 | 2022 |
| Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019; 9: 1349–1357. doi: 10.1158/2159-8290 L Vuong, RR Kotecha, MH Voss, AA Hakimi CD-19-0499.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 31 | |
| High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab CH Lee, RG DiNatale, D Chowell, C Krishna, V Makarov, C Valero, ... Molecular Cancer Research 19 (9), 1510-1521, 2021 | 22 | 2021 |
| A targetable myeloid inflammatory state governs disease recurrence in clear-cell renal cell carcinoma PM Rappold, L Vuong, J Leibold, NH Chakiryan, M Curry, F Kuo, E Sabio, ... Cancer discovery 12 (10), 2308-2329, 2022 | 13 | 2022 |
| IRF8 governs tumor-associated macrophage control of T cell exhaustion BG Nixon, F Kuo, M Liu, K Capistrano, M Do, RA Franklin, X Wu, ... BioRxiv, 2020.03. 12.989731, 2020 | 7 | 2020 |
| Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019; 9 (10): 1349-1357. doi: 10.1158/2159-8290 L Vuong, RR Kotecha, MH Voss, AA Hakimi CD-19-0499, 0 | 7 | |
| Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019; 9: 1349–57 L Vuong, RR Kotecha, MH Voss, AA Hakimi | 7 | |
| Resistance to anti-PD-1/anti-PD-L1: Galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1 J Mabbitt, ID Holyer, JA Roper, UJ Nilsson, FR Zetterberg, L Vuong, ... Frontiers in Immunology 14, 1250559, 2023 | 3 | 2023 |
| High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab. CH Lee, RG DiNatale, D Chowell, C Krishna, V Makarov, C Valero, ... Molecular cancer research: MCR 19 (9), 1510, 2021 | 3 | 2021 |
| PD51-12 COMPREHENSIVE IMMUNOGENOMIC EVALUATION OF PATIENTS UNDERGOING CONSOLIDATIVE CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNE … S Reese, V Yarlagadda, CY Wu, F Kuo, C Tang, H Jiang, M Dawidek, ... The Journal of Urology 211 (5S), e1071, 2024 | | 2024 |
| COMPREHENSIVE IMMUNOGENOMIC EVALUATION OF PATIENTS UNDERGOING CONSOLIDATIVE CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT … S Reese, V Yarlagadda, CY Wu, F Kuo, C Tang, H Jiang, LH Vuong, ... Urologic Oncology: Seminars and Original Investigations 42, S44, 2024 | | 2024 |
| Tumor immune microenvironment determinants of response to lenvatinib and a PD-1 blockade in clear cell renal cell carcinoma L Vuong, F Kuo, H Jiang, EA Mascareno, P Rappold, E Sabio, K Weiss, ... CANCER RESEARCH 83 (16), 2023 | | 2023 |
